S. Fürst

发表

[CAR-T cells: Lymphocytes that express a chimeric antigen receptor].

R. Bouabdallah, D. Blaise, C. Chabannon, 2019, La Revue de medecine interne.

Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.

D. Blaise, Wang LiNing, R. Devillier, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

TLI in refractory chronic GVHD

D. Blaise, R. Devillier, L. Castagna, 2013, Bone Marrow Transplantation.

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes

D. Blaise, C. Carlo-Stella, R. Devillier, 2016, Bone Marrow Transplantation.

Reduced‐intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma

R. Bouabdallah, L. Xerri, D. Blaise, 2006, British journal of haematology.

Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma

R. Bouabdallah, B. Chetaille, D. Blaise, 2014, Hematological oncology.

Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison

D. Blaise, M. Mohty, D. Coso, 2009, Leukemia.

Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant

B. Esterni, D. Blaise, M. Mohty, 2010, Leukemia & lymphoma.

Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome

R. Bouabdallah, A. Santoro, D. Blaise, 2020, Bone Marrow Transplantation.

Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction

D. Blaise, J. Rey, C. Arnoulet, 2012, Leukemia & lymphoma.

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.

I. Yakoub-Agha, J. Bay, G. Socié, 2019, Blood advances.

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.

I. Yakoub-Agha, J. Bay, Z. Medeghri, 2017, Blood.

Inolimomab in steroid-resistant aGvHD 1 A phase III randomized trial comparing Inolimomab vs . Usual care in steroid-resistant acute GVHD

I. Yakoub-Agha, J. Bay, Z. Medeghri, 2016 .

Randomized study of 2 reduced‐intensity conditioning strategies for human leukocyte antigen‐matched, related allogeneic peripheral blood stem cell transplantation

D. Blaise, M. Mohty, V. Bardou, 2013, Cancer.

Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT

R. Bouabdallah, D. Blaise, C. Oudin, 2013, Bone Marrow Transplantation.

Optimization of health-care organization and perceived improvement of patient comfort by switching from intra-venous BU four-times-daily infusions to a once-daily administration scheme in adult hematopoietic stem cell recipients

S. Santarone, C. Scheid, W. Krüger, 2014, Bone Marrow Transplantation.

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

R. Bouabdallah, A. Santoro, D. Blaise, 2015, Haematologica.

Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Leukemia and Lymphoma.

Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation

R. Bouabdallah, D. Blaise, R. Devillier, 2019, Bone Marrow Transplantation.

HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.

D. Blaise, R. Devillier, S. Harbi, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Successful treatment of post-transplant Epstein–Barr virus-related meningoencephalitis by intravenous rituximab monotherapy

D. Blaise, C. Oudin, R. Devillier, 2012, Leukemia & lymphoma.

High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation

R. Bouabdallah, D. Blaise, M. Mohty, 2007, Bone Marrow Transplantation.

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT)

X. Thomas, S. Hayette, F. Nicolini, 2005, Bone Marrow Transplantation.

Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients.

R. Bouabdallah, D. Blaise, C. Oudin, 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

D. Blaise, R. Devillier, S. Harbi, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.

R. Bouabdallah, B. Esterni, D. Blaise, 2010, Experimental hematology.

Allogeneic hematopoietic SCT and mechanical heart valve: feasibility of reduced toxicity myeloablative conditioning

D. Blaise, R. Devillier, N. Vey, 2010, Bone Marrow Transplantation.

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus on Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

R. Bouabdallah, D. Blaise, R. Devillier, 2012, Mediterranean journal of hematology and infectious diseases.

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

R. Bouabdallah, D. Blaise, M. Mohty, 2008, Bone Marrow Transplantation.

Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies

D. Blaise, M. Mohty, S. Ederhy, 2022, Bone Marrow Transplantation.

Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.

J. Wagner, M. Mohty, P. Dreger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective study on perineal lacerations in vaginal delivery and the individual performance of experienced mifwives

R. Seemann, S. Fürst, J. Ott, 2015, BMC Pregnancy and Childbirth.

Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

S. Chevret, P. Chevallier, I. Yakoub-Agha, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit.

J. Blache, D. Blaise, L. Castagna, 2015, Journal of critical care.

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

D. Blaise, A. Nagler, M. Mohty, 2008, Haematologica.

Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.

R. Bouabdallah, D. Blaise, R. Devillier, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry.

M. Robin, I. Yakoub-Agha, D. Blaise, 2013, Experimental hematology.

Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning

P. Chevallier, D. Blaise, M. Mohty, 2013, Leukemia.

Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for hematologic diseases

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Cancer.

Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients

R. Bouabdallah, D. Blaise, R. Devillier, 2018, Bone Marrow Transplantation.

A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor

R. Bouabdallah, D. Blaise, D. Coso, 2014, American journal of hematology.

Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients

R. Bouabdallah, D. Blaise, R. Devillier, 2019, Bone Marrow Transplantation.

Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

D. Blaise, M. Mohty, J. Bay, 2012, Annals of Hematology.

Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced‐intensity conditioning regimens

X. Thomas, F. Nicolini, V. Dubois, 2005, British journal of haematology.

S. Chevret, M. Mohty, J. Larghero, 2018, Blood.

JC Virus Leuko-Encephalopathy in Reduced Intensity Conditioning Cord Blood Transplant Recipient with a Review of the Literature

D. Blaise, C. Oudin, L. Castagna, 2012, Mediterranean Journal of Hematology and Infectious Diseases.

JC Virus Leuko-Encephalopathy Transplant Recipient with a R

C. Oudin, L. Castagna, C. Faucher, 2012 .

Rituximab as salvage therapy for refractory chronic GVHD

D. Blaise, M. Mohty, N. Marchetti, 2008, Bone Marrow Transplantation.

Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes

D. Blaise, Jiong Hu, R. Devillier, 2018, Bone Marrow Transplantation.

Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.

R. Bouabdallah, D. Blaise, D. Coso, 2011, Experimental hematology.

Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma

R. Bouabdallah, D. Blaise, C. Oudin, 2013, Bone Marrow Transplantation.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

R. Bouabdallah, D. Blaise, C. Oudin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT

B. Esterni, D. Blaise, R. Devillier, 2012, Bone Marrow Transplantation.

Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma

D. Blaise, S. Fürst, 2022, The EBMT/EHA CAR-T Cell Handbook.

Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.

D. Blaise, M. Mohty, H. de Lavallade, 2006, Haematologica.

Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data.

M. Sormani, D. Blaise, C. Oudin, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission

R. Bouabdallah, D. Blaise, M. Mohty, 2006, Bone Marrow Transplantation.

Long-term graft-versus-Waldenström macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation

R. Bouabdallah, D. Blaise, M. Mohty, 2007, Bone Marrow Transplantation.

Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial

P. Chevallier, D. Blaise, M. Mohty, 2015, Haematologica.

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available

R. Bouabdallah, D. Blaise, D. Coso, 2015, Bone Marrow Transplantation.

Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells

D. Blaise, R. Devillier, S. Harbi, 2018, British journal of haematology.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML

D. Blaise, R. Devillier, S. Harbi, 2017, Bone Marrow Transplantation.

Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?

R. Bouabdallah, D. Blaise, M. Mohty, 2012, Leukemia & lymphoma.

Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.

D. Blaise, R. Devillier, S. Harbi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin.

D. Blaise, C. Chabannon, H. de Lavallade, 2009, Blood.

Low incidence of chronic GVHD after HLA‐haploidentical peripheral blood stem cell transplantation with post‐transplantation cyclophosphamide in older patients

D. Blaise, R. Devillier, S. Harbi, 2017, British journal of haematology.

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available

R. Bouabdallah, D. Blaise, D. Coso, 2015, Bone Marrow Transplantation.

Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia

D. Blaise, R. Devillier, J. Rey, 2013, Leukemia & lymphoma.

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT

R. Bouabdallah, B. Esterni, D. Blaise, 2011, Bone Marrow Transplantation.

Impact of CD34‐positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG‐based reduced intensity conditioning regimen

D. Blaise, R. Devillier, S. Harbi, 2017, American journal of hematology.

Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantation.